From a single web-based portal, fund managers gain increased transparency across OTC trade lifecycles and are able to demonstrate independent portfolio pricing and valuation confirmation to investors.

GlobeOp, a leading independent fund administrator, currently processes approximately 3% of the daily global OTC derivatives trade volume. Its robust, scalable GoOTC platform supports full post-trade lifecycle management - trade capture, valuation, reconciliation, operations, collateral management and documentation. The new features enable fund managers to filter portfolios based on reconciliation and confirmation status, and to drill down to and compare trade-specific valuation details.

"Our goal with these enhancements is to bring our clients closer to their data," said Jon Anderson, global head of OTC derivatives at GlobeOp. "Greater transparency and independent valuation is a priority across funds, from the front office to risk managers and fund investors. Access to timely, detailed derivative trade status data supports daily trading strategies, collateral management and overall portfolio management. Funds can also benefit from reduced operational cost and risk as straight-through processing (STP) is delivered on a single, integrated derivatives processing platform."

The valuation enhancements include increased visibility of comparative detail as available from multiple pricing sources. Trade valuation and tolerance status is available, as well as current and historical valuations. New reconciliation process monitoring enables fund managers to access counterparty position and valuation reconciliations. Drill-downs to breaks and resolution audit trails are possible. Trade status transparency includes customised reconciliation and trade documentation search criteria. Color-coded indicators provide fund managers with a quick overview of reconciliation and confirmation processes.

Anderson continued: "Among fund administration service providers, GlobeOp is committed to and recognised for deep OTC knowledge and expertise, and for providing leading edge buy-side OTC services. These enhancements reflect our continuing development of services that provide clients with greater transparency and automation benefits. In addition, our significant technology investments provide clients with scale and instrument coverage that most funds could not achieve on their own."